PHA 2024

The Pulmonary Hypertension Association's biennial conference brings together more than 1,300 people with pulmonary hypertension, caregivers and health care professionals. The conference focuses on the latest research and treatments, ways to thrive with PH, and opportunities to participate in research and connect with others in the PH community. The theme for this year's conference is "Stronger Together." 




A limited number of scholarships for PHA 2024 are still available!  

Please apply for your PHA 2024 scholarship prior to registering for the conference.  
Once you are notified of your scholarship application decision you will be given instructions on how to proceed with registration.

Scholarships are awarded on a first-come, first-serve basis. You must be current PHA member to apply for a scholarship.  Membership status will be verified prior to scholarships being awarded.  If you are not a current member, please email our membership department.   If you are living with PH and experiencing financial difficulty, please use this form email Member Services to request a one-year complimentary membership.

 Apply Now


Conference Agenda     Scientific Sessions Agenda 

Featured Sessions

PHA/PVRI Joint Session: The Real-World Evidence in PAH

Traditional randomized clinical trials are  powerful tools for developing scientific evidence about therapeutic interventions. RCTs guide regulatory approval of new drugs and devices, and are the foundation of clinical guidelines. Yet, RCTs recruit highly selected populations and manage them in controlled settings, which makes it difficult to generalize the results to broader, diverse populations seen  in clinical practice. Clinicians, regulators, payers and the pharmaceutical industry increasingly recognize the use of real‐world evidence to complement to knowledge gained from RCTs. During this session, the presenters will discuss the meaning of RWE in the context of pulmonary arterial hypertension, as well as  regulatory requirements for therapy approval based on  real-world evidence.

Featured Presenters:

Jean Elwing, MD, FCCP

Elwing Photo

Kari R. Gillmeyer, MD, MSc

Gillmeyer Photo

Sandeep Sahay, MD, MSc

Sahay Photo

Greg Elliott, MD, MACP

Elliott Photo

Teresa De Marco, MD, FACC, FHFSA 

DeMarco Photo


Changing the Paradigm in Treating Patients with Pulmonary Hypertension and Parenchymal Lung Disease

Description: Pulmonary hypertension, which often occurs alongside parenchymal lung disease, significantly worsens the prognosis compared to having either condition alone. In this session, speakers will explore interstitial lung disease, chronic obstructive pulmonary disease and pediatric lung disease-associated pulmonary hypertension. The session will include a discussion of prior studies of pulmonary vasodilators; methods to identify patients with ILD and COPD who may respond to systemic pulmonary vasodilators; the success of the INCREASE trial and how to optimize the use of inhaled treprostinil. The session also will address future directions in studying this complex condition and unique challenges associated with  pediatric patients.

Featured Presenters:

Nicholas Kolaitis, MD, MAS

Kolaitis Photo

Oksana Shlobin, MD

Shlobin Photo

Jordin Rice, RN, BSN

Rice Photo

Maidah Yaqoob, MD

Yaqoob Photo

Yuri Matusov, MD, FACP

Matusov Photo

Oisin O’Corragain, MD

O'Carragain Photo


PHA2024 Stronger Together

Programs and Activities

Learn more about PHA 2024 programs and activities:




Travel and Safety

JW  Marriott

Hotel Information

JW Marriott Indianapolis
10 S West St 
Indianapolis, IN 46204

Click here for information about planning your trip to Indianapolis.



PHA 2024 Conference Committee

Nicole Creech, Patient: Co-Chair, 
Traci Stewart, RN: Co-Chair
Diane Brakin, MSN, APRN, AGNP-C
Nancy Elena Rivas Elizondo, Caregiver
Rachel Hopper, MD
Jessie Kohler, JD, Patient 
Fran Rogers, CRNP